DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Free Report) CFO Glenn Coleman purchased 10,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was acquired at an average price of $29.70 per share, with a total value of $297,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 73,566 shares in the company, valued at approximately $2,184,910.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
DENTSPLY SIRONA Stock Up 0.8 %
Shares of NASDAQ:XRAY traded up $0.25 during midday trading on Monday, hitting $29.94. 3,186,338 shares of the company’s stock traded hands, compared to its average volume of 2,111,260. The firm’s fifty day moving average price is $32.00 and its two-hundred day moving average price is $36.58. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.04 and a current ratio of 1.57. DENTSPLY SIRONA Inc. has a twelve month low of $26.27 and a twelve month high of $43.24. The company has a market cap of $6.34 billion, a PE ratio of -29.48, a P/E/G ratio of 2.04 and a beta of 0.99.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.01. DENTSPLY SIRONA had a positive return on equity of 10.91% and a negative net margin of 5.44%. The company had revenue of $947.00 million for the quarter, compared to analysts’ expectations of $975.21 million. During the same quarter in the previous year, the firm posted $0.41 earnings per share. The firm’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.82 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently commented on XRAY. Needham & Company LLC assumed coverage on DENTSPLY SIRONA in a research note on Thursday. They issued a “buy” rating and a $35.00 target price for the company. StockNews.com raised shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Barrington Research decreased their target price on shares of DENTSPLY SIRONA from $51.00 to $41.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd. The Goldman Sachs Group dropped their price target on shares of DENTSPLY SIRONA from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, November 7th. Finally, Stifel Nicolaus decreased their price target on shares of DENTSPLY SIRONA from $35.00 to $32.00 and set a “hold” rating on the stock in a report on Monday, November 13th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, DENTSPLY SIRONA currently has an average rating of “Moderate Buy” and a consensus price target of $38.89.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in XRAY. Wellington Management Group LLP lifted its holdings in DENTSPLY SIRONA by 83.1% in the 1st quarter. Wellington Management Group LLP now owns 5,502,424 shares of the medical instruments supplier’s stock worth $270,829,000 after buying an additional 2,497,773 shares in the last quarter. Norges Bank purchased a new position in DENTSPLY SIRONA in the fourth quarter valued at about $60,861,000. Silvercrest Asset Management Group LLC grew its stake in DENTSPLY SIRONA by 242.2% during the 2nd quarter. Silvercrest Asset Management Group LLC now owns 2,100,859 shares of the medical instruments supplier’s stock valued at $84,076,000 after purchasing an additional 1,486,931 shares in the last quarter. Armistice Capital LLC increased its holdings in DENTSPLY SIRONA by 169.9% during the 1st quarter. Armistice Capital LLC now owns 2,256,000 shares of the medical instruments supplier’s stock worth $88,616,000 after purchasing an additional 1,420,000 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of DENTSPLY SIRONA by 85.0% in the 4th quarter. Lazard Asset Management LLC now owns 2,992,857 shares of the medical instruments supplier’s stock valued at $95,292,000 after purchasing an additional 1,375,285 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products.
- Five stocks we like better than DENTSPLY SIRONA
- Dividend Tax Calculator
- The most upgraded stocks in November have two things in common
- Learn Technical Analysis Skills to Master the Stock Market
- Monday.com rocked earnings like it’s the weekend
- Financial Services Stocks Investing
- Plan to own one retailer? Make it this one
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.